Overview of Zibor

Quick Facts

Property	Description
Active ingredient	Bemiparin Sodium
Form	Solution for Injection (pre-filled syringes)
Pharmacological class	Anticoagulant, Low Molecular Weight Heparin (LMWH)
Common use	Prevention of Venous Thromboembolism (VTE)
Origin	Semi-synthetic (derived from porcine mucosal heparin)

What Type of Medicine is Zibor? (Identity and Classification)

Zibor is a prescription Anticoagulant and Antithrombotic agent, primarily utilized for the prevention of blood clot formation. Its sole active component is Bemiparin Sodium, which is classified within the Low Molecular Weight Heparins (LMWHs) group.

Bemiparin is distinguished as a second-generation LMWH, possessing specific characteristics that include a mean molecular mass of approximately 3,600 Daltons and a high anti-Factor Xa to anti-Factor IIa ratio of 8:1. This specialized profile allows it to achieve predictable and sustained anticoagulant activity, making it an important consideration among modern LMWH alternatives.

Composition, Origin, and Form

The active entity, Bemiparin Sodium, is a semi-synthetic substance originating from unfractionated heparin of medical-grade porcine mucosal tissue. It is produced through controlled chemical depolymerisation and fractionation.

Zibor is presented as a sterile, aqueous Solution for Injection, supplied as a single-ingredient product. It is primarily packaged in pre-filled syringes for administration via subcutaneous injection. The preparation of Bemiparin is associated with a long half-life, a key factor that supports the maintenance of continuous antithrombotic prophylaxis.

What is the General Purpose of Bemiparin Sodium? (High-Level Benefit)

The fundamental purpose of Zibor is antithrombotic prophylaxis, meaning its function is dedicated to preventing the occurrence of blood clots, particularly venous thromboembolism (VTE). The medicine achieves this by selectively binding to Antithrombin III, which in turn results in the focused inactivation of Factor Xa, a crucial enzyme required for the blood to clot.

Regulatory References

National Cancer Institute, NCI

What side effects are possible with Zibor?

Possible Side Effects and Safety Information

The official safety profile for Zibor (Bemiparin Sodium) is primarily defined by its function as an anticoagulant, with side effects formally classified by frequency and body system in regulatory documents (e.g., EMA/HPRA SmPC).

Adverse Reaction Classification

The most commonly documented adverse reactions are linked to bleeding. Common (ge 1/100 to < 1/10) effects include bleeding and injection site hematoma, as well as mild transient thrombocytopenia (Type I HIT), which is typically observed at the start of therapy.

Frequency Category	Associated Adverse Reactions (Examples)
Rare (ge 1/10,000 to < 1/1,000)	Severe antibody-mediated thrombocytopenia (Type II HIT), Cutaneous necrosis
Very Rare (< 1/10,000)	Epidural or spinal hematoma, which may lead to paralysis

Serious Adverse Reactions and Systemic Effects

Serious reactions documented in regulatory sources include major hemorrhage, severe antibody-mediated thrombocytopenia (Type II HIT), and epidural or spinal hematoma. System-organ-class groupings include effects on Blood and Lymphatic System Disorders (e.g., thrombocytopenia), Vascular Disorders (e.g., hemorrhage), and Skin and Subcutaneous Tissue Disorders (e.g., cutaneous necrosis).

Population-Specific and Duration-Related Safety Notes

Safety constraints exist for specific populations. Caution is required in patients with severe renal impairment (creatinine clearance < 30 mL/min) and liver failure due to potential impacts on the medicine's clearance and increased bleeding risk. Hyperkalaemia (raised plasma potassium levels) is a documented risk that appears to increase with the duration of therapy, requiring monitoring, especially if treatment extends beyond seven days. Absolute regulatory restrictions include a history of Type II HIT and active hemorrhage.

Overdose and Emergency Response

The official overdose profile for Zibor (Bemiparin Sodium) is explicitly defined by regulatory authorities based on the consequences of excessive anticoagulant activity, which mandates specific emergency actions.

Documented Overdose Manifestations

Feature	Regulatory Statement
Primary Clinical Sign	Overdose, especially following administration by non-subcutaneous routes, may lead to hemorrhagic complications (bleeding). This is the chief documented manifestation of excessive use, consistent with the drug's class.
Specific Severe Outcome	A potential severe, life-threatening risk is the development of spinal/epidural haematoma when Zibor is used in the context of neuraxial procedures. This complication requires defined urgent intervention.
Risk Consideration	The official documents note that patients with severe renal impairment (creatinine clearance less than 30 mL/min) are at an increased risk of LMWH toxicity due to the effects of impaired clearance kinetics on Bemiparin.

Regulator-Mandated Emergency Actions

Feature	Required Action
Urgent Medical Help	You must seek immediate medical attention or go immediately to the casualty department if an overdose is suspected or if any signs of unusual or unexpected bleeding are observed.
Specific Intervention	The regulatory label documents that the anticoagulant effect can be neutralized by the slow intravenous administration of the antidote Protamine Sulfate.
Neurological Event	If symptoms of neurological impairment, such as back pain or motor deficits, are suspected, urgent diagnosis and treatment including spinal cord decompression are officially mandated procedures.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the Zibor overdose profile based on the drug's potential to cause hemorrhagic complications when administered in excess. This explicitly requires the immediate reporting of suspected overdose or any observed bleeding to medical professionals. The label provides the framework for managing this toxicity, specifying the necessary procedural steps and the required antidote.

Therapeutic Uses of Zibor

Zibor (Bemiparin Sodium) is an anticoagulant agent commonly used to manage the risk of blood clot formation in both preventative and acute management contexts. Its primary uses include the prevention of Venous Thromboembolism (VTE), such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), the treatment of established acute DVT, and procedural support to help manage clotting during hemodialysis.

Prevention and Management

In clinical settings involving acute or unstable symptom patterns, such as after major general or orthopedic surgery (e.g., hip or knee replacement), Zibor is applied to reduce the likelihood of dangerous clots. It is commonly used to help manage the physiological stress associated with acute illness or recovery from surgery. When used prophylactically, it provides necessary support that helps ease the overall symptom burden associated with VTE risk.

“For patients with a confirmed clot, its benefit assists with managing the risk associated with an established condition.”

For patients with a confirmed clot, its therapeutic benefit assists with managing the risk associated with an established clot, which may assist with maintaining functional stability during the acute phase. In renal care, it helps support continuous and stable blood flow during external procedures.

Quick Fact: Relief for Pathological Blood Clot Risk
Category of Use: Thromboprophylaxis and Acute DVT Management
Primary Benefit: Manages the risk of VTE (DVT and PE) and supports functional stability during dialysis.

Regulatory References

Summary of Product Characteristics (SmPC) reviewed by the HPRA

Eligibility and Restrictions for Use

Who can and cannot use Zibor?

This section outlines the official eligibility and non-eligibility rules for Zibor (Bemiparin Sodium) as defined by government regulatory documents.

Eligibility Scope

Category	Eligibility Rule (Official Regulatory Statement)
Allowed Use	Intended for use in Adult Patients Only.
Not Recommended	Use is not recommended for children and adolescents (pediatric patients).

Populations for whom use is Contraindicated

Zibor is absolutely prohibited for use in patients with:

Hypersensitivity to Bemiparin Sodium, heparin, or substances of porcine origin.
History of immunologically mediated Heparin-Induced Thrombocytopenia (HIT).
Active Hemorrhage or conditions causing a high risk of bleeding, such as hemorrhagic stroke, cerebral aneurysm, or active peptic ulcer.
Severe impairment of liver or pancreas function.
Acute bacterial endocarditis or recent injuries/operations on the central nervous system, eyes, or ears.

Eligibility-Related Restrictions

Use is permitted only under strict conditions and monitoring for certain populations:

Severe Renal Impairment (creatinine clearance less than 30 mL/min) requires regular monitoring as the drug’s clearance may be affected.
Pregnancy and Lactation is conditional; use is allowed only if the potential benefits outweigh the possible risks due to limited clinical data.

Connection to the overall eligibility profile

Regulatory documents define eligibility based on the highest safety risks associated with this anticoagulant, primarily bleeding potential and immunological history. The profile strictly limits use to adults and formalizes exclusions for severe comorbidities or bleeding risks, classifying all other non-excluded populations by conditional use or prohibition.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Zibor (Bemiparin Sodium) outlines interactions primarily based on additive pharmacological effects, which are classified as pharmacodynamic interactions. The main concern is an officially documented increase in the risk of bleeding or hemorrhage when Zibor is co-administered with other agents that affect coagulation or platelet function.

Co-administration is not advisable with several classes of medicinal products that increase the bleeding risk. These include:

Other Anticoagulants, such as Vitamin K antagonists (e.g., Warfarin).
Antiplatelet Drugs, including Acetylsalicylic acid (Aspirin) and Clopidogrel.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
Systemic Glucocorticoids.

Another documented pharmacodynamic interaction involves medicines that increase the serum potassium concentration, such as certain diuretics or anti-hypertensives. Concomitant use with these agents requires especially careful medical supervision, particularly for patients with conditions like chronic renal failure or diabetes mellitus, due to the additive risk of hyperkalemia.

A mandatory administration restriction also applies: the intramuscular injection of any other medicinal product must be avoided during treatment with Zibor to prevent the formation of a hematoma at the injection site. Finally, an interaction observed with unfractionated heparin, where Intravenous Nitroglycerine may result in a decrease in anticoagulant efficacy, is noted in regulatory documents as a possibility that cannot be ruled out for Zibor.

Mechanism of Action

️ How Zibor Works

The mechanism of Zibor (Bemiparin Sodium) is focused entirely on the enzymatic process of blood clotting, inducing an antithrombotic state by acting as an accelerator of a natural inhibitor.

Selective Amplification of Antithrombin III

The drug initiates its effect by binding to the plasma protein Antithrombin III (AT III), causing a rapid structural change that accelerates its inhibitory activity. This interaction is the cornerstone of the mechanism, as it converts AT III into an extremely efficient neutralizing agent for specific coagulation enzymes. The resulting physiological consequence is a suppression of the blood's intrinsic clotting capacity.

Targeted Disruption of the Coagulation Cascade

The primary target of the activated AT III complex is Factor Xa (FXa), an enzyme critical for propagating the Common Coagulation Pathway. By selectively and irreversibly neutralizing FXa, Zibor limits the large-scale generation of Thrombin (Factor IIa), which is the enzyme needed to form the fibrin clot. This upstream blockage of the cascade is the mechanism that results in the systemic suppression of fibrin formation and polymerization.

Mechanistic Selectivity and Limitation

Zibor is engineered for a high degree of selectivity, concentrating its action predominantly on FXa, evidenced by its low potential to inhibit Thrombin (FIIa). This inherent molecular constraint means the mechanism is best characterized by its capacity for inhibiting the potential for clot propagation, rather than neutralizing Thrombin that is already physically bound within an established clot structure.

Dosage and Administration Information

Administration Scope and Dosing

Zibor (Bemiparin Sodium) is an anticoagulant administered as a Subcutaneous (SC) injection for standard use, following a once-daily frequency. The Intramuscular route is strictly forbidden. The solution is supplied in ready-for-use pre-filled syringes, which must not be purged of air bubbles prior to injection.

Dosage is defined by anti-Factor Xa International Units (IU). For VTE prophylaxis, standard doses are either 2,500 IU or 3,500 IU. Treatment of established clots follows a weight-based regimen of 115 IU/kg once daily, corresponding to fixed doses of 5,000 IU to 10,000 IU based on weight category. A fixed dose of 2,500 IU or 3,500 IU is also used as an intra-arterial bolus for anticoagulation during haemodialysis.

Timing and Procedural Conditions

For surgical prophylaxis, the first dose must be administered either two hours before surgery or six hours after surgery. The SC injection site is designated as the anterolateral or posterolateral abdominal waist, with required alternation between sides. The needle must be inserted perpendicularly into a skin fold, and the site must not be rubbed after administration. A distinct procedural constraint mandates that a subsequent dose must be delayed for at least four hours following the removal of a spinal or epidural catheter.

Duration and Population Rules

Prophylaxis is typically continued for a minimum of 7 to 10 days or until the patient is fully mobile. For clot treatment, the duration is typically 7 to 10 days and is followed by a transition to oral anticoagulants once the therapeutic International Normalized Ratio (INR) is achieved. The product is not recommended for children as supporting data are unavailable, and caution with close monitoring is required for adult patients with severe renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zibor (Bemiparin Sodium)

Evidence for Preventing Blood Clots After Surgery (VTE Prophylaxis)

Research on Zibor has been evaluated in controlled trials focusing on patients who meet criteria for Venous Thromboembolism (VTE) risk following major surgery. Researchers utilized numerous Randomized Controlled Trials (RCTs) and comparative studies, which are designed to compare Zibor against other anticoagulants. These studies monitored outcomes reflecting systemic or functional imbalance by measuring the incidence of confirmed VTE (including DVT and PE).

Findings indicate that the medicine was studied for use in the prophylaxis setting (risk reduction focus) in adults undergoing major orthopedic or general surgery. Long-term research outcomes remain uncertain; follow-up durations were typically limited to the immediate hospital stay and up to 30 days post-discharge. The persistence of the initial study findings is not fully established beyond this intermediate period.

Research on Treating Confirmed Deep Vein Thrombosis (DVT)

Zibor was also studied for the management of an established blood clot in the acute phase of treatment. These trials primarily consisted of Randomized Controlled Trials comparing Zibor against therapies like intravenous Unfractionated Heparin (UFH). The studies monitored two main outcomes: the change in thrombus size and the prevention of a clinical recurrence of VTE during the initial treatment months.

This data is described as being derived from a limited number of well-controlled trials. Long-term effects are not fully established beyond the intermediate 12-week period; thus, there is limited information comparing the long-term secondary prevention outcomes against oral therapies. Subgroup findings are uncertain for complex patient groups, such as those with active cancer.

Key Gaps and Areas of Research Uncertainty

While the data show patterns related to VTE incidence after surgery, research provides context but not individual predictions. Key limitations include the modest sample sizes in many DVT treatment and dialysis studies, and comparative evidence is lacking against the full array of LMWH and oral anticoagulant alternatives for all studied indications. Overall, the long-term effects beyond the first few months of use are not fully established.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Zibor (FAQ)

Q: How quickly should I expect Zibor to start working?

Official product information on how Zibor works indicates a rapid onset of its anticoagulant effect. Regulatory information indicates that the onset of effect is rapid, with peak anti-Factor Xa activity typically observed around 1 to 2 hours after administration.

Q: Can taking Zibor make you feel tired or dizzy?

Official information generally advises caution regarding potential systemic side effects. Dizziness has been noted as a potential adverse effect associated with anticoagulants, but tiredness or fatigue is not typically listed as one of the commonly reported side effects for Zibor.

Q: Are there any serious side effects I should watch out for with Zibor?

Yes, regulatory documents list several serious adverse reactions. These include major hemorrhage (severe bleeding), severe allergic reactions, and severe antibody-mediated thrombocytopenia (a serious drop in platelet count known as Type II HIT). Patients should seek immediate medical assistance if they experience any signs or symptoms of these serious adverse reactions.

Q: Does Zibor interact with herbal remedies like St. John's Wort?

While specific herbal remedies like St. John's Wort are not always explicitly listed, regulatory warnings advise general caution. This is because any product, including certain herbal supplements, that might affect the blood's ability to clot or platelet function could potentially increase the risk of bleeding when used concurrently with Zibor.

Q: Does taking Zibor affect driving or operating machinery?

According to official product information, Zibor is not expected to impair the ability to drive or operate heavy machinery. However, patients should be mindful of any potential adverse effects, such as dizziness, that could affect their concentration or reaction time.

Q: What does Zibor do inside the body to help?

Zibor is an anticoagulant that works by targeting the blood clotting process. It achieves this by binding to a natural plasma protein called Antithrombin III, which significantly speeds up the inactivation of a clotting factor known as Factor Xa. Blocking Factor Xa is the mechanism that results in the antithrombotic state, reducing the blood's capacity to form clots.

Q: Is Zibor available over the counter, or is it prescription only?

Zibor is strictly a prescription-only medicine (POM). It must be prescribed by a licensed healthcare professional and is not available for over-the-counter purchase.

Q: How long does Zibor stay in your system after you stop taking it?

Pharmacokinetic data from regulatory sources indicate that Zibor has a relatively long plasma half-life of approximately 5.3 hours. This half-life suggests that the anticoagulant activity is sustained for several hours.

Q: Does alcohol interact negatively with Zibor?

The official safety information advises patients to discuss the use of alcohol with their prescriber. This is because while a direct interaction specific to Zibor is not always known, alcohol consumption may affect the general safety and efficacy of anticoagulant therapy.

Q: What foods or supplements should be avoided while on Zibor?

Specific food lists are not provided for Zibor. Official guidance often recommends maintaining consistent Vitamin K intake and caution regarding supplements that may affect blood clotting (e.g., high-dose Vitamin E). Patients should consult their healthcare provider about their diet and supplements.

Q: What happens if I miss a dose of Zibor?

The official instructions address a missed dose, generally advising patients not to take a double dose to compensate for the missed one. Specific guidance for missed doses is detailed in the Patient Information Leaflet provided with the medicine.

Q: What happens if I accidentally take too much Zibor?

Overdose is associated with an increased risk of bleeding. If an overdose is suspected, medical emergency services should be contacted immediately. Regulatory documents confirm that the anticoagulant effect can be largely reduced by the slow intravenous administration of protamine sulfate by a healthcare professional.

Q: How long can a person safely stay on Zibor?

The recommended duration of use is determined by the specific condition being treated, such as a minimum of 7 to 10 days for surgical prophylaxis. Official research overviews note that the long-term effects and safety are often not fully established beyond these intermediate treatment periods in the available studies.

Q: Why do some people experience stomach upset when taking Zibor?

While the core official side effect profile focuses on bleeding and injection site reactions, general warnings for anticoagulants may include gastrointestinal issues. Therefore, mild stomach upset or indigestion may be a possible, though less common, side effect.

Q: Does Zibor require any special monitoring (like blood tests) while taking it?

Routine coagulation monitoring is generally not required for Zibor because of its predictable pharmacological profile. However, patients are monitored for any signs of bleeding, and closer supervision may be required for individuals with certain conditions, such as severe renal (kidney) impairment.

Q: Do you need to take Zibor with food, or can it be taken on an empty stomach?

Since Zibor is a solution administered via injection, its absorption and effect are independent of whether it is taken with food or on an empty stomach.

Q: Are there any known allergic reactions to Zibor?

Yes, allergic reactions are a possibility. Hypersensitivity to the active ingredient, heparin, or porcine-derived substances is listed in official documents as a contraindication (a reason to avoid use). Severe allergic reactions are also listed as rare adverse effects.

Q: Can Zibor be crushed or split if someone has trouble swallowing pills?

This question does not apply to Zibor. Official documents confirm Zibor is provided as a sterile solution in a pre-filled syringe intended for injection, not as a tablet or capsule that can be crushed or split.

Q: Does Zibor have any effect on blood pressure?

Although Zibor is not a blood pressure medicine, a significant drop in blood pressure may occur as a sign of a serious hemorrhagic event (bleeding). This potential is noted as an indirect systemic risk associated with the drug class.

Q: What kind of research has been done on Zibor?

Official information states that the research supporting Zibor has primarily consisted of Randomised Controlled Trials (RCTs) and comparative studies. These studies investigated its use for preventing venous thromboembolism (VTE) after major surgery and for the treatment of established deep vein thrombosis (DVT).

Q: Where can I find reliable information about clinical trials for Zibor?

Reliable, official information regarding clinical trials for Zibor is typically available on governmental regulatory websites and official clinical trial registries, such as those maintained by the European Medicines Agency (EMA) or the National Institutes of Health (ClinicalTrials.gov).

Q: Does Zibor interact with birth control pills?

The regulatory documents for Zibor do not specifically list an interaction with oral birth control pills. Information for this specific interaction is often generalized; official documents recommend discussing all concomitant medications, including hormonal contraceptives, with a healthcare provider.

Q: Are there specific symptoms that mean I should stop taking Zibor immediately?

The official product leaflet advises patients to seek urgent medical attention for any signs of major bleeding or severe allergic reactions. These specific symptoms indicate a severe adverse reaction that requires immediate medical assessment.

Q: Does Zibor have a risk of dependence or addiction?

Based on its safety profile and pharmacological class, the regulatory documents contain no information suggesting that Zibor carries any risk of dependence or addiction.

How should Zibor be stored and disposed of?

How to Store and Dispose of Zibor (Bemiparin Sodium)

Official regulatory documents define strict storage and disposal requirements for Zibor solution for injection.

Storage Conditions

Zibor must be stored in a refrigerator at a temperature between 2 C and 8 C. It is mandatory to keep the product in its original package to ensure protection from light. The medicine must not be frozen as this can compromise the stability of the solution. The product must also be stored out of the sight and reach of children.

Disposal Instructions

Disposal of Zibor involves specific procedures for the used injection devices and for unused medicine.

Used pre-filled syringes must be placed immediately into a dedicated puncture-resistant sharps container. Used sharps must not be thrown into household trash. Any unused or expired Zibor product, or the contents of the sharps container, must be disposed of in accordance with local pharmaceutical waste regulations.

Zibor